高级管理人员持有股份的基本情况 截至本公告披露日，公司财务负责人、副总经理谭勇先生持有公司股份 571,440 股，占公司总股本的比例为 0.14%。其中 515,440 股为无限售流通股， 来源为公司首次公开发行股票并上市前取得的股份以及非交易过户取得的股份， 56,000 股为限售流通股，来源为股权激励取得的股份。 证券代码：688319 证券简称：欧林生物 公告编号：2025-045 成都欧林生物科技股份有限公司 高级管理人员减持股份计划公告 本公司董事会、全体董事及相关股东保证本公告内容不存在任何虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律 责任。 重要内容提示： 截至本公告披露日，公司董事会秘书、副总经理吴畏先生持有公司股份 778,400 股，占公司总股本的比例为 0.19%。其中 714,000 股为无限售流通股， 来源为公司首次公开发行股票并上市前取得的股份以及非交易过户取得的股份， 64,400 股为限售流通股，来源为股权激励取得的股份。 减持计划的主要内容 公司于近日收到高级管理人员谭勇先生和吴畏先生出具的告知函，根据自身 财务规划，谭勇先生和吴畏先生 ...

格隆汇9月4日丨欧林生物(688319.SH)公布，公司于近日收到高级管理人员谭勇先生和吴畏先生出具的 告知函，根据自身财务规划，谭勇先生和吴畏先生计划通过集中竞价交易方式减持其持有的公司股份分 别不超过128,860股和178,500股，自本次减持股份计划公告披露之日起15个交易日后的3个月内实施。 ...

欧林生物(688319.SH)发布公告，公司于近日收到高级管理人员谭勇先生和吴畏先生出具的告知函，根 据自身财务规划，谭勇先生和吴畏先生计划通过集中竞价交易方式减持其持有的公司股份分别不超过 12.89万股和17.85万股，自本次减持股份计划公告披露之日起15个交易日后的3个月内实施。 ...

智通财经APP讯，欧林生物(688319.SH)发布公告，公司于近日收到高级管理人员谭勇先生和吴畏先生 出具的告知函，根据自身财务规划，谭勇先生和吴畏先生计划通过集中竞价交易方式减持其持有的公司 股份分别不超过12.89万股和17.85万股，自本次减持股份计划公告披露之日起15个交易日后的3个月内实 施。 ...

一、信息披露义务人及其一致行动人的基本信息 1.身份类别 ■ 2.信息披露义务人信息 ■ 登录新浪财经APP 搜索【信披】查看更多考评等级 本公司董事会、全体董事及相关股东保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏， 并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： ■ 本次权益变动后，上海武山与一致行动人樊绍文、樊钒合计持有公司的股份数量由11,864.1245万股减少 至11,772.0745万股，占公司总股本的比例由29.22%减少至29.00%，权益变动触及1%刻度，具体情况如 下： ■ 三、其他说明 1、本次权益变动属于上海武山通过集中竞价交易方式履行此前披露的减持股份计划，公司实际控制人 樊绍文、樊钒以及公司董事陈爱民承诺通过上海武山间接持有的股份不参与本次减持。具体内容详见公 司于2025年7月23日在上海证券交易所网站（www.sse.com.cn）披露的《成都欧林生物科技股份有限公 司股东减持股份计划公告》（公告编号：2025-030）。 2、本次权益变动为公司控股股东的正常减持，不触及要约收购，亦不会导致公司的控股股东及实际控 制人发生变化，不会对公司治理 ...

证券代码：688319 证券简称：欧林生物 公告编号：2025-044 成都欧林生物科技股份有限公司关于持股 5%以上股 东权益变动触及 1%刻度的提示性公告 本公司董事会、全体董事及相关股东保证本公告内容不存在任何虚假记载、误导 性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 权益变动方向 比例增加□ 比例减少√ 权益变动前合计比例 29.22% 权益变动后合计比例 29.00% 本次变动是否违反已作出的承 是□ 否√ 诺、意向、计划 是否触发强制要约收购义务 是□ 否√ 一、 信息披露义务人及其一致行动人的基本信息 √控股股东/实际控制人及其一致行动人 □其他 5%以上大股东及其一致行动人 投资者及其一致行动人的身份 □合并口径第一大股东及其一致行动人（仅适用 于无控股股东、实际控制人） □其他______________（请注明） 信息披露义务人名称 投资者身份 统一社会信用代码 √控股股东/实控人 上海武山生物技术有 □ 控股股东/实控人的一致 √915001036939216618 限公司 行动人 □ 不适用 □ 其他直接持股股东 一致行动人名称 投资者身份 ...

证券代码：688319 证券简称：欧林生物 公告编号：2025-044 重要内容提示： | 权益变动方向 | 比例增加□ | | 比例减少√ | | --- | --- | --- | --- | | 权益变动前合计比例 | 29.22% | | | | 权益变动后合计比例 | 29.00% | | | | 本次变动是否违反已作出的承 | 是□ | 否√ | | | 诺、意向、计划 | | | | | 是否触发强制要约收购义务 | 是□ | 否√ | | 一、 信息披露义务人及其一致行动人的基本信息 成都欧林生物科技股份有限公司关于持股 5%以上股 东权益变动触及 1%刻度的提示性公告 本公司董事会、全体董事及相关股东保证本公告内容不存在任何虚假记载、误导 性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 1.身份类别 | | √控股股东/实际控制人及其一致行动人 | | --- | --- | | | □其他 5%以上大股东及其一致行动人 | | 投资者及其一致行动人的身份 | □合并口径第一大股东及其一致行动人（仅适用 | | | 于无控股股东、实际控制人） | | | □其他__ ...

Core Viewpoint - The company, Olin Bio (688319.SH), has decided to terminate its planned private placement of shares due to current market conditions and internal assessments, despite the ongoing progress of its vaccine research and production base technology renovation project [1][2]. Group 1: Company Overview - Olin Bio is headquartered in Chengdu and has three core products: Tetanus Toxoid Vaccine, Hib Conjugate Vaccine, and AC Conjugate Vaccine, with the Tetanus Toxoid Vaccine maintaining a leading market share in China [1]. - The company has a GMP base of approximately 80,000 square meters, which includes three bulk production lines, four filling lines, two packaging lines, one R&D center, one quality inspection center, and one experimental animal center [1]. Group 2: Fundraising and Financials - The planned private placement aimed to raise 175 million yuan for the technology renovation project, which has a total investment of approximately 290 million yuan [2]. - As of the first half of 2025, Olin Bio reported cash and cash equivalents of 184 million yuan and total liabilities of 902 million yuan, indicating potential cash flow pressure if the technology renovation project proceeds without the planned fundraising [2]. Group 3: Market Reaction and Stock Performance - Following the announcement of the private placement, Olin Bio's stock price surged from 16.17 yuan on June 17 to 28.87 yuan by September 2, representing an increase of over 78% [3]. - The company’s significant stock price increase raised concerns among investors about potential market overheating, especially as the private placement price was set significantly lower than the current market price [3][2]. Group 4: Shareholder Actions - Shortly after the private placement announcement, the controlling shareholder, Shanghai Wushan Biotechnology Co., Ltd., announced a plan to reduce its holdings by up to 12.18 million shares, representing no more than 3% of the company's total share capital [4].

Core Viewpoint - Chengdu Olin Biological Technology Co., Ltd. has decided to terminate its plan for a simplified procedure to issue shares to specific targets due to current market conditions and company circumstances, stating that this decision will not adversely affect its daily operations or shareholder interests [1][2]. Company Overview - Olin Biological primarily engages in the research, production, and sales of human vaccines, with key products including adsorbed tetanus vaccine, Hib conjugate vaccine, and AC conjugate vaccine, which are the main sources of revenue and cash flow [3]. Financial Performance - In the first half of 2025, Olin Biological achieved operating revenue of 306 million yuan, a year-on-year increase of 35.17%, and net profit attributable to shareholders of 13.2 million yuan, marking a turnaround from losses [3]. - As of June 30, 2025, the company reported total assets of 1.836 billion yuan, a 1.62% increase from the beginning of the year, with total liabilities of 902 million yuan, reflecting a 3.24% increase [3]. Fundraising and Investment Plans - The initial plan for the share issuance aimed to raise 175 million yuan to invest in the vaccine research and production base renovation project, which has a total investment of 290 million yuan [2]. - The project was intended to upgrade production facilities for various vaccine products, thereby optimizing production processes and expanding product lines [2].

Group 1 - Weisheng Information won four projects in August with a total amount of 85.5377 million yuan, accounting for 3.12% of the company's total revenue for 2024 [1] - Longqi Technology's shareholder plans to reduce its stake by up to 4.09%, equating to a maximum of 19.1916 million shares [1] - Guojin Modern's subsidiary received a drug registration certificate for injectable Nicardipine, used for treating unstable angina [3][4] Group 2 - SAIC Motor reported a total vehicle sales of 363,400 units in August, a year-on-year increase of 41.04%, with new energy vehicle sales reaching 129,800 units, up 49.89% [5] - Kuka Home plans to invest 1.124 billion yuan to build a self-owned base in Indonesia, aiming to enhance its international strategy [6] - Samsung Medical's subsidiary signed a contract for an intelligent meter project in Egypt worth 58.8 million USD, approximately 419 million yuan [8] Group 3 - North Vehicle Blue Valley's subsidiary reported a total production of 10,587 units in August, a year-on-year decrease of 15.13%, while sales increased by 3.47% [12] - Xianghe Industrial signed contracts worth 400 million yuan for railway fastener system components [13] - Hengrui Medicine's HRS9531 injection has received acceptance for its marketing authorization application [14] Group 4 - Hualu Hengsheng resumed normal production after completing maintenance on production facilities [16] - Shanghai Pharmaceuticals' hydrochloride verapamil injection passed the consistency evaluation for generic drugs [18] - Shanghai Construction received approval for debt financing tools with a registration period of two years [20] Group 5 - Kangli Elevator terminated the sale of its wholly-owned subsidiary due to the buyer's failure to obtain necessary approvals [21] - Times Wan Heng appointed Li Zhizhong as the new deputy general manager [22] - Hanma Technology reported a total truck sales of 1,051 units in August, a year-on-year increase of 58.05% [24] Group 6 - Wenzhou Hongfeng's subsidiary received a utility model patent certificate for a servo adjustment device [26] - Yibin Technology received a project designation from a domestic new energy vehicle company, with an estimated total sales of 243 million yuan over five years [28] - Star Ring Technology's H-share issuance application was accepted by the China Securities Regulatory Commission [30] Group 7 - Microchip Bio's vice president resigned for personal reasons [31] - Zhongxin Co. announced the resignation of a non-independent director due to personal reasons [32] - Changcheng Military Industry's vice chairman resigned due to retirement [35] Group 8 - Jiukang Bio received four invention patent certificates related to detection reagents [36] - Meino Bio's subsidiary changed its registered address [37] - Kuangda Technology announced a potential change in control due to a share transfer [38] Group 9 - China Rare Earth confirmed no undisclosed significant matters amid stock price fluctuations [72]